Sun Aug 31 17:50:00 UTC 2025: **Summary:**
New research indicates that beta-blockers, a long-standing first-line treatment after a heart attack, may not benefit most patients with preserved heart function and could even be harmful to some women. The study found that women with normal heart function after a heart attack who were treated with beta-blockers had a higher risk of another heart attack, hospitalization for heart failure, and death. The findings challenge current guidelines that recommend beta-blockers for all post-heart attack patients, regardless of ejection fraction. Researchers suggest a sex-specific approach to cardiovascular treatment is needed.
**News Article:**
**Groundbreaking Study Questions Routine Use of Beta-Blockers After Heart Attack, Especially for Women**
Madrid, Spain – A new study is challenging decades of conventional wisdom regarding the use of beta-blockers following a heart attack. The research, presented at the European Society of Cardiology Congress in Madrid and published in the *European Heart Journal* and *The New England Journal of Medicine*, suggests that these drugs may not benefit the majority of patients and could even be detrimental to some women.
The study, part of the larger REBOOT trial involving over 8,500 patients, found that beta-blockers offered no benefit to individuals with normal heart function (left ventricular ejection fraction above 50%) after a heart attack. More alarmingly, women in this group treated with beta-blockers had a significantly higher risk of recurrent heart attacks, heart failure hospitalizations, and death compared to those not receiving the medication.
“These findings will reshape all international clinical guidelines on the use of beta-blockers,” said Dr. Valentin Fuster, president of Mount Sinai Fuster Heart Hospital and a senior author of the study. He advocated for a “sex-specific approach” to cardiovascular treatment.
Specifically, the study found that women with preserved heart function who were on high doses of beta-blockers experienced worse outcomes. However, the researchers emphasize that beta-blockers remain the standard of care for patients with impaired heart function (ejection fraction below 40%) after a heart attack, as demonstrated by the meta-analysis published in *The Lancet*.
Experts speculate that differences in heart size, sensitivity to blood pressure medication, and other factors may contribute to women’s increased vulnerability to the potential adverse effects of beta-blockers. Furthermore, heart disease presents differently in men and women.
Dr. Borja Ibáñez, lead study author, noted that while new drugs are routinely tested, older treatments are rarely rigorously re-evaluated. He also added that the separate meta-analysis of 1,885 patients published in The Lancet “did find benefits for those with scores between 40% and 50%, in which the heart may be mildly damaged.”
These findings are poised to spark debate and revision of current medical guidelines, potentially leading to more personalized and sex-specific approaches to post-heart attack care. This could mean fewer patients, especially women, are routinely prescribed beta-blockers after a heart attack.
First Piper 